SUBSCRIBERS

Trendlines says its most valuable portfolio company is Stimatix

Stimatix sold its assets in Nov 2014 to a B Braun subsidiary; Trendlines' current holding of 28.2% valued at US$42.6m

Published Mon, Apr 9, 2018 · 09:50 PM

Singapore

CATALIST-LISTED The Trendlines Group - an Israel and Singapore-based incubator of medtech and agritech startups - has disclosed that an asset it described as its "Most Valuable Portfolio Company" is Stimatix GI.

In a statement on Monday, Trendlines said that Stimatix, which develops medical products to aid patients with intestinal blockage, sold its assets in November 2014 to a subsidiary of German medical device company B Braun Group. B Braun will market Stimatix's ostomy products internationally from mid-2018.